Summary by Moomoo AI
On March 12, 2024, Biora Therapeutics, Inc. was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by several entities and individuals. Context Capital Management, LLC, along with Michael S. Rosen, William D. Fertig, Charles E. Carnegie, and Context Partners Master Fund, L.P., reported shared voting and dispositive power over 2,989,698 shares of Biora Therapeutics' common stock, representing 0.9% of the class. The filing clarified that these parties are not forming a group and each disclaims beneficial ownership of the securities except to the extent of their pecuniary interest. The shares in question are issuable upon conversion of Convertible Senior Notes due 2028, subject to a 9.9% ownership limitation. The reported percentage ownership is based on 27,209,277 shares of Biora Therapeutics' common stock outstanding as of December 20, 2023. The filing was completed on March 20, 2024, with all parties certifying that the acquisition of shares is in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.